Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.
Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.
Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.
Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections. You may also view the abstract by clicking on the article link.
Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.
Latest features in GaBI Journal, 2021, Issue 3 / Professor Philip D Walson, MD
Pharmacokinetics and bioequivalence of generic etoricoxib in healthy volunteers / Nishalini Harikrishnan, BSc; Ka-Liong Tan, DPhil; Kar Ming Yee, BPharm; Alia Shaari Ahmad Shukri, MSc; Nalla Ramana Reddy, MBBS; Chuei Wuei Leong, PhD
Reasons for patients’ generic drug switching at the pharmacy counter: a pilot study / Pieter J Glerum, MSc; Mert Hayta, PharmD, MSc; David M Burger, PharmD, PhD; Cees Neef, PharmD, PhD; Marcel L Bouvy, PharmD, PhD; Marc Maliepaard, PhD
Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI®) in polyolefin bags and elastomeric devices / Lyndsay Davies, PhD; Katie Milligan, BSc; Mark Corris, BSc; Ian Clarke1; Paul Dwyer, MSc; Sarah Elizabeth Lee, PhD; Jolene Teraoka, BSc; Jill Crouse-Zeineddini, PhD; Jane Hippenmeyer, PharmD
A critical review of substitution policy for biosimilars in Canada / Michael S Reilly, Esq, Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP
Microbiological, scientific and regulatory perspectives of hand sanitizers / Adjunct Associate Professor Sia Chong Hock, BSc Pharm, MSc; Tan Ying Ting, BSc Pharm (Hons); Associate Professor Chan Lai Wah, BSc Pharm (Hons)
The European framework for intellectual property rights for biological medicines / Josette Sciberras, MBA, MA Bioethics, BPharm (Hons); Raymond Zammit, SThD; Patricia Vella Bonanno, PhD
Biotechnological therapies and biosimilars for COVID-19: scarcities, poor regulation, and pharmaceutical black market: a case analysis in Ecuador / Esteban Ortiz-Prado, MD, MSc, MPH, PhD; Enrique Teran, MD, PhD; Raul Patricio Fernandez Naranjo, MSc; Doménica Cevallos-Robalino, MD; Eduardo Vasconez1, MD; Alex Lister, MPH
Regulatory pathway for approval of ‘biosimilars’ in Iran / Jalal Naeli, MD
Use of biologicals in dermatology – following the agreed path or going off-piste? A brief report / Michael Wilcock, MPhil; Andrew Pothecary, MSc
Biosimilar epoetin for cancer and chemotherapy-induced anaemia in the US / Charles L Bennett, MD
Abstracted Scientific Content
Click here for more details on the educational series.
Contact us for an updated list of editorial topics in forthcoming issues.
*Editorial content may differ from final version of manuscript published in print.